Inogen, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Kevin R. Smith
- Full Time Employees
- 753
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 500 Cummings Center Beverly MA United States of America 01915
- IPO Date
- Feb 14, 2014
- CIK
- 0001294133
- Website
- inogen.com
- Similar Companies
- Business
- Inogen, Inc. (Nasdaq: INGN) develops, manufactures, and markets innovative portable oxygen concentrators and respiratory therapy devices for patients with chronic respiratory conditions in the homecare setting; core products include the Inogen One series (G4, G5), Rove 6 with six pulse dose settings and up to 12.8 hours of battery life, and the recently initiated Simeox airway clearance device; the company sells directly to consumers, rents units domestically, and distributes business-to-business to home medical equipment providers, prescribers, and international partners. Founded in 2001 and headquartered in Goleta, California, Inogen operates globally with manufacturing in Texas and California using sourced components, generating majority revenue in the United States while serving Canada, Europe, Asia-Pacific, and Latin America through distributors and large gas companies. In early 2025, Inogen secured a $27.2 million strategic collaboration with Yuwell, including a 9.9% equity investment closing in Q1 to expand product portfolio, global reach, and innovation pipeline via respiratory product distribution; the company reports seven consecutive quarters of mid-single-digit revenue growth through Q3 2025, achieving positive adjusted EBITDA and initiating limited U.S. release of Simeox.
Dimensional Fund Advisors LP Reduces Position in Inogen, Inc $INGN
Should Investors Buy Inogen as Low Valuation Meets Execution Risk?
Inogen Cuts 2026 Revenue Outlook as U.S. Channel Pressure Persists
Inogen Q2 Earnings Beat Estimates, Sales Rise Y/Y, 2026 View Cut
Inogen, Inc. (INGN) Q2 2026 Earnings Call Transcript
Inogen Q2 Earnings Call Highlights
Inogen (INGN) Reports Q2 Loss, Tops Revenue Estimates
Inogen Announces Second Quarter 2026 Financial Results
Inogen to Report Second Quarter 2026 Financial Results on August 6, 2026
Inogen Announces the Appointment of Andy Reding as Chief Operating Officer
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen, Inc. (INGN) Q1 2026 Earnings Call Transcript
INGN Stock Dips on Q1 Earnings Miss, Sales Up Y/Y, Gross Margin Improves
Inogen (INGN) Reports Q1 Loss, Beats Revenue Estimates
Inogen Announces First Quarter 2026 Financial Results
Inogen (NASDAQ:INGN) Stock Price Passes Above 50 Day Moving Average – Here’s What Happened
Inogen to Report First Quarter 2026 Financial Results on May 7, 2026
Here's Why You Should Retain Inogen Stock in Your Portfolio for Now
Inogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?